Cost-effectiveness of widespread screening for Chlamydia trachomatis

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 10, 2002, Pages 1443-1450

  Postma, Maarten J ^a   Welte, Robert ^a   Morré, Servaas A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antibiotics; Chlamydia trachomatis; Cost effectiveness; Screening; Sexually transmitted diseases

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; PROBENECID; TETRACYCLINE;

ADOLESCENT; ADULT; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA PROBE; DRUG COST; ECONOMIC ASPECT; ECTOPIC PREGNANCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HUMAN; MALE; NETHERLANDS; NUCLEIC ACID AMPLIFICATION; REVIEW; SCREENING; SEXUALLY TRANSMITTED DISEASE; TISSUE CULTURE; WESTERN EUROPE;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MASS SCREENING; NETHERLANDS; PREGNANCY;

EID: 0036796338     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.10.1443     Document Type: Review

References (48)

1. VAN HULST M, DE WOLF JTM, STAGINNUS U, RUITENBERG EJ, POSTMA MJ: Pharmaco-economics of blood transfusion safety; reviewing the available evidence. Vox Sang (2002) 83(2):146-155.
2. ADES AE, RADCLIFFE J, GIBB DM, SCULPHER MJ: Economic issues in the prevention of vertical transmission of HIV. Pharmacoeconomics (2000)18:9-22.
3. POSTMA MJ, BECK EJ, MANDALIA S et al.: Universal HIV screening of pregnant women in England: cost effectiveness analysis. Br. Med. J. (1999)318:1656-1660.
4. BINDELS PJE, POSTMA MJ, PEERBOOMS PGH, COUTINHO RA, VAN DEN HOEK JAR: The positive effect of serological screening for syphilis during pregnancy in Amsterdam in the period 1985 - 1989. Nederlands Tijdschrift voor Geneeskunde (1991) 135:1319-1322.
5. DWYER MJ, MCINTYRE PG: Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area. Epidemiol. Infect. (1996)117:121-131.
6. Bundesauschuss der Ärzte und Krankenkassen. Mutterschaftsrichtlinien. Bundesanzeiger (1996) 37.
7. HERMANN B, EGGER M: Genital Chlamydia trachomatis infections in Uppsala County, Sweden, 1985 - 1993: declining rates for how much longer? Sex. Transm. Dis. (1995)22:253-260.
8. WALSH C, ANDERSON LA, IRWIN K: The silent epidemic of Chlamydia trachomatis: the urgent need for detection and treatment in women. J. Womens Health Gend. Based (2000)9:339-343.
9. ANDERSON RM, MAY RM: Infectious diseases of humans; dynamics and control. Oxford University Press, New York, NY, USA (1991).
10. POSTMA MJ, WELTE R, VAN DEN HOEK JAR et al.: Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis. Health Econ. Prevention Care (2000)1:103-110.
11. STAMM WE, GUINAN ME, JOHNSON C, STARCHER T, HOLMES KK, MCCORMACK WM: Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. New Engl. J. Med. (1984)310:545-549.
12. SCHOLES D, STERGACHIS A, HEIDRICH FE, ANDRILLA H, HOLMS KK, STAMM WE: Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. New Engl. J. Med. (1996) 334:1362-1366.
13. WESTRÖM L, JOESEOF R, REYNOLDS G, HAGDU A, THOMPSON SE: Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. Transm. Dis. (1992) 19:185-191.
14. EGGER M, LOW N, SMITH GD, LINDBLOM B, HERMAN B: Screening for chlamydial infections and the risk of ectopic pregancy in a county of Sweden: ecological analysis. Br. Med. J. (1998) 316:1776-1780.
15. KAMWENDO F, FORSLIN F, BODIN L, DANIELSSON D: Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex. Transm. Dis. (1996) 23:384-391.
16. KAMWENDO F, FORSLIN F, BODIN L, DANIELSSON D: Programmes to reduce pelvic inflammatory disease - the Swedish experience. Lancet (1998) 351(Suppl.III): 25-28.
17. SCHACHTER J, GROSSMAN M, SWEET RL, HOLT J, JORDAN C, BISHOP E: Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA (1986) 255:3374-3377.
18. SCHACHTER J, SWEET RL, GROSSMAN M, LANDERS D, ROBBIE M, BISHOP E: Experience with the routine use of erythromycin for chlamydial infections in pregnancy. N. Engl. J. Med. (1986) 314:276-279.
19. RYAN Jr GM, ABDELLA TN, MCNEELEY SG, BASELSKI VS, DRUMMOND DE: Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am. J. Obstet. Gynecol. (1990) 162:34-39.
20. SCHACHTER J, GROSSMAN M: Chlamydial infections. Ann. Rev. Med. (1981) 32:45-61.
21. SMITH JR, TAYLOR-ROBINSON D: Infection due to Chlamydia trachomatis in pregnancy and the newborn. Baillieres Clin. Obstet. Gynaecol. (1993) 7:237-255.
22. MANGIONE-SMITH R, O'LEARY J, MCGLYNN EA: Health and cost-benefits of Chlamydia screening in young women. Sex. Transm. Dis. (1999) 26:309-316.
23. WELTE R, JAGER JC, POSTMA MJ: Cost-effectiveness of screening for genital Chlamydia trachomatis. Expert Rev. Pharmacoeconom. Outcomes Res. (2001) 2:145-156.
24. MORRÉ SA, VAN VALKENGOED IGM, MOES RM et al.: Determination of the Chlamydia trachomatis prevalence in an asymptomatic screening population; performance of LCx and COBAS amplicor in urine specimens. J. Clin. Microbiol. (1999) 37:3092-3096.
25. KACENA KA, QUINN SB, HOWELL MR, MADICO, GE, QUINN TC, GAYDOS CA: Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J. Clin. Microbiol. (1998) 36:481-485.
26. MORRÉ SA, MEIJER CJLM, MUNK C et al.: Pooling of urine specimens for the detection of Chlamydia trachomatis by PCR in a low prevalence population: cost saving strategy for epidemiological studies and screening programs. J. Clin. Microbiol. (2000) 38:1679-1680.
27. PEELING RW, TOYE B, JESSAMINE I, GEMMILL I: Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex. Transm. Inf. (1998) 74:66-70.
28. MORRÉ SA, WELTE R, POSTMA MJ.: Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing. Sex. Transm. Inf. (2002) 78:74-75.
29. GENÇ M, MÅRDH PA: Cost-effective treatment of uncomplicated gonorrhea including co-infection with Chlamydia trachomatis. Pharmacoeconom. (1997) 12:374-383.
30. TURRENTINE MA, NEWTON ER. Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis. Obst. Gynecol. (1995) 86:1021-1025.
31. WEHBEH HA, RUGGEIRIO RM, SHAHEM S, LOPEZ G, ALI Y: Sinle-dose azithromycin for Chlamydia in pregnant women. J. Reprod. Med. (1998) 43:509-514.
32. BOS JM, FENNEMA JSA, POSTMA MJ: Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS (2001) 15:2031-2078.
33. SOMANI J, BHULLAR VB, WORKOWSKI KA, FARSHY CE, BLACK CM: Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. (2000) 181:1421-1427.
34. STEPHENS RS, KALMAN S, LAMMEL C et al.: Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science (1998) 282:754-759.
35. VAN DEN HOEK JAR, MULDER-FOLKERTS DDF, COUTINHO RA, DUKERS NHTM, BUIMER M, VAN DOORNUM GJJ: Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population of Amsterdam (in Dutch). Ned. Tijaschr. Geneeskd. (1999) 143:668-672.
36. NYARI T, NYARI C, WOODWARD M, MESZAROS G, DEAK J, NAGY E, KOVACS L: Screening for Chlamydia trachomatis in asymptomatic women in Hungary; an epidemiological and cost-effectiveness analysis. Acta Obstet. Gynecol. Scand. (2001) 80:300-306.
37. GENÇ M, MÅRDH PA. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann. Intern. Med. (1996) 124:1-7.
38. HOWELL MR, MCKEE KT, GAYDOS JC, QUINN TC, GAYDOS CA. Point-of-entry screening for C. trachomatis in female army recruits; who deserves the cost savings? Am. J. Prev. Med. (2000) 19:160-166.
39. VAN VALKENGOED IGM, POSTMA MJ, MORRÉ SA, et al:. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex. Transm. Inf. (2001) 77:276-282.
40. POSTMA MJ, BAKKER A, WELTE R, et al.: Screening for asymptomatic infection with Chlamydia trachomatis in pregnancy; favourable cost-effectiveness at prevalences above 3% (in Dutch). Ned. Tijdschr. Geneeskd. (2000) 144:2350-2354.
41. GOLD MR, SIEGEL JE, RUSSEL LB, WEINSTEIN MC: Cost-effectiveness in Health and Medicine. Oxford University Press, New York, NY, USA (1996).
42. POSTMA MJ, WELTE R, VAN DEN HOEK JAR, MORRÉ SA: Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches. Sex. Transm. Inf. (2002) 78:73-74.
43. QUIN TC, GAYDOS C, SHEPHERD M et al.: Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA (1996) 276:1737-1742.
44. GENÇ M, RUUSUVAARA L, MÅRDH P-A: An economic evaluation of screening for Chlamydia trachomatis in adolescent males. JAMA (1993) 17:2057-2064.
45. POSTMA MJ, WELTE R, VAN DEN HOEK JAR, VAN DOORNUM GJJ, JAGER JC, COUTINHO RA. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis. Value in Health (2001) 4:266-275.
46. KRETZSCHMAR M, WELTE R, VAN DEN HOEK JAR, POSTMA MJ: Comparative Model-based Analysis of Screening Programs for Chlamydia trachomatis Infections. Am. J. Epidemiol. (2001) 153:90-101.
47. WELTE R, KRETZSCHMAR M, LEIDL R, VAN DEN HOEK JAR, JAGER JC, POSTMA MJ: Cost-effectiveness of screening programs for Chlamydia trachomatis. Sex. Transm. Dis. (2000) 27:518-529.
48. WELTE R, KRETZSCHMAR M, JAGER JC, LEIDL R, VAN DEN HOEK JAR, POSTMA MJ: Opportunistic screening for genital infection with Chlamydia trachomatis among the sexually active population of Amsterdam. IV. Cost-effectiveness analysis of screening including the dynamics of the spread of an infectious disease in a population. Ned. Tijdschr. Geneeskd. (2002)